Flash FinanceUS
Pre-market S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · United Therapeutics (UTHR)

United Therapeutics posts record Q2 2025 revenue of $798.6 million, up 12%

Positive Impact 3 of 5 earnings Written later

United Therapeutics reported record second quarter 2025 total revenue of $798.6 million, up 12 percent from $714.9 million a year earlier, and net income of $309.5 million, up 11 percent. Diluted EPS rose 10 percent to $6.41, and the Board authorized share repurchases of up to $1 billion expiring March 31, 2026.

Key points

  • Total revenue $798.6 million vs. $714.9 million in Q2 2024, up 12 percent
  • Tyvaso DPI revenue $315.2 million, up 22 percent; Nebulized Tyvaso $154.4 million, up 10 percent
  • Net income $309.5 million vs. $278.1 million; diluted EPS $6.41 vs. $5.85
  • Share repurchase authorization of up to $1 billion, expiring March 31, 2026; $21.7 million PP&E impairment recorded

The filing

CompanyUnited Therapeutics (UTHR)
Form8-K, current report
Filed with the SECJul 30, 2025, 6:36 AM ET
Accession number0001628280-25-036543

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 1:10 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on July 30, 2025.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.